Primary Mucosa-Associated Lymphoid Tissue Lymphoma of the Salivary Glands: A Multicenter Rare Cancer Network Study
- Department of Radiation Oncology, Ege University Medical School, Izmir (Turkey)
- Department of Radiation Oncology, Mayo Clinic, Rochester, MN (United States)
- Department of Hematology, Theagenion Cancer Center, Thessaloniki (Greece)
- Division of Hematology, Armando Businco Cancer Center, Cagliari (Italy)
- Department of Oncology, Rambam Medical Center, Haifa (Israel)
- Department of Radiation Oncology, Cancer Hospital of Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (China)
- Servicio de Oncologia Radioterapica, Institut Catala d'Oncologia, Barcelona (Spain)
- Department of Oncology and Radiotherapy, Medical University of Gdansk (Poland)
- Department of Radiation Oncology, Geneva University Hospital (Switzerland)
- Department of Radiation Oncology, University of Massachusetts Medical School/Center, North Worcester, MA (United States)
- Department of Radiation Oncology, Istanbul University Cerrahpasa Medical School, Istanbul (Turkey)
- Institute Verbeeten, Tilburg (Netherlands)
- Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne (Switzerland)
Purpose: Involvement of salivary glands with mucosa-associated lymphoid tissue (MALT) lymphoma is rare. This retrospective study was performed to assess the clinical profile, treatment outcome, and prognostic factors of MALT lymphoma of the salivary glands. Methods and Materials: Thirteen member centers of the Rare Cancer Network from 10 countries participated, providing data on 63 patients. The median age was 58 years; 47 patients were female and 16 were male. The parotid glands were involved in 49 cases, submandibular in 15, and minor glands in 3. Multiple glands were involved in 9 patients. Staging was as follows: IE in 34, IIE in 12, IIIE in 2, and IV in 15 patients. Results: Surgery (S) alone was performed in 9, radiotherapy (RT) alone in 8, and chemotherapy (CT) alone in 4 patients. Forty-one patients received combined modality treatment (S + RT in 23, S + CT in 8, RT + CT in 4, and all three modalities in 6 patients). No active treatment was given in one case. After initial treatment there was no tumor in 57 patients and residual tumor in 5. Tumor progression was observed in 23 (36.5%) (local in 1, other salivary glands in 10, lymph nodes in 11, and elsewhere in 6). Five patients died of disease progression and the other 5 of other causes. The 5-year disease-free survival, disease-specific survival, and overall survival were 54.4%, 93.2%, and 81.7%, respectively. Factors influencing disease-free survival were use of RT, stage, and residual tumor (p < 0.01). Factors influencing disease-specific survival were stage, recurrence, and residual tumor (p < 0.01). Conclusions: To our knowledge, this report represents the largest series of MALT lymphomas of the salivary glands published to date. This disease may involve all salivary glands either initially or subsequently in 30% of patients. Recurrences may occur in up to 35% of patients at 5 years; however, survival is not affected. Radiotherapy is the only treatment modality that improves disease-free survival.
- OSTI ID:
- 22055955
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 82, Issue 1; Other Information: Copyright (c) 2012 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Salvage Treatment Improved Survival of Patients With Relapsed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Primary spinal epidural lymphoma: Patients' profile, outcome, and prognostic factors: A multicenter Rare Cancer Network study